Literature DB >> 18095116

Pathological and clinical features of cystic and noncystic glioblastomas.

Satoshi Utsuki1, Hidehiro Oka, Sachio Suzuki, Satoru Shimizu, Yoshinori Tanizaki, Koji Kondo, Satoshi Tanaka, Nobuyuki Kawano, Kiyotaka Fujii.   

Abstract

The aim of this study is to review the different histological and clinical characteristics of glioblastoma multiforme (GBM) with and without cysts (cystic and noncystic GBM, respectively). Thirty-seven GBM were collected; these were tumors for which more than 80% of the volume was surgically resected, including a portion of the peripheral parenchyma of the brain. Based on preoperative magnetic resonance (MR) imaging studies, tumors were tentatively classified as cystic GBM if more than 50% of their volume appeared to be liquid; otherwise, they were considered to be noncystic GBM. Tumor volumes were estimated from contrast-enhanced T1-weighted MR images. Edema was deduced from the maximum width of contrast-enhanced edges. Peritumoral pathological analysis showed distinct margins, indicating little or no infiltration of tumor cells into white matter. Five cases were classified as cystic and 32 were noncystic GBMs. There was a statistically significant difference in age (Mann-Whitney U test; P < 0.05) between the patients with cystic tumors (median, 44 years; range, 26-59 years) and those with noncystic tumors (median, 54 years; range, 26-81 years). Four of the cystic tumors and eight of the noncystic tumors were more than 5 cm in maximum diameter. Cystic GBMs had a well-defined tumor interface and less than 2-cm-thick peritumoral edema compared to the noncystic GBMs (Fisher's exact test; P < 0.05). For patients with cystic GBMs, median survival time after surgery was 19.8 months and the 2-year survival rate was 50%. Patients with noncystic GBMs had a median survival time of 12.8 months and a 2-year survival rate of only 17%. Median time to tumor recurrence was 13.3 months for patients harboring cystic GBMs and 8.5 months for those with noncystic GBMs (log-rank test; P < 0.05). Thus, the prognosis for cystic GBM was significantly better than that for noncystic GBM, possibly because cystic GBMs showed comparatively little infiltration of the peritumoral brain parenchyma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18095116     DOI: 10.1007/s10014-006-0195-8

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  19 in total

1.  Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.

Authors:  Patrizia Farina; Emeline Tabouret; Pierre Lehmann; Maryline Barrie; Gregorio Petrirena; Chantal Campello; Celine Boucard; Thomas Graillon; Nadine Girard; Olivier Chinot
Journal:  J Neurooncol       Date:  2017-03-06       Impact factor: 4.130

2.  Rare case of glioblastoma multiforme located in posterior corpus callosum presenting with depressive symptoms and visual memory deficits.

Authors:  Hale Yapıcı-Eser; Aslıhan Onay; Özgür Öztop-Çakmak; Emrah Egemen; Ebru Nur Vanlı-Yavuz; İhsan Solaroğlu
Journal:  BMJ Case Rep       Date:  2016-12-15

3.  Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent.

Authors:  Ying Geng; Latika Kohli; Barbara J Klocke; Kevin A Roth
Journal:  Neuro Oncol       Date:  2010-01-27       Impact factor: 12.300

4.  Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Authors:  J A Carrillo; A Lai; P L Nghiemphu; H J Kim; H S Phillips; S Kharbanda; P Moftakhar; S Lalaezari; W Yong; B M Ellingson; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-09       Impact factor: 3.825

5.  Midline glioblastoma multiforme with bilateral symmetric cysts.

Authors:  Hai-Ong Lee; Eun-Jeong Koh; Young-Min Oh; Ha-Young Choi
Journal:  J Korean Neurosurg Soc       Date:  2008-02-20

6.  Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.

Authors:  Kai Wang; Yinyan Wang; Xing Fan; Jiangfei Wang; Guilin Li; Jieling Ma; Jun Ma; Tao Jiang; Jianping Dai
Journal:  Neuro Oncol       Date:  2015-09-25       Impact factor: 12.300

Review 7.  Intracranial cystic lesions: a review.

Authors:  Sophie Taillibert; Emilie Le Rhun; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

8.  Bilateral cystic glioblastoma multiforme.

Authors:  Sushil Kumar; Amit Handa; Rohan Sinha; Ravi Tiwari
Journal:  J Neurosci Rural Pract       Date:  2013-10

9.  MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication.

Authors:  J Zhou; M V Reddy; B K J Wilson; D A Blair; A Taha; C M Frampton; R A Eiholzer; P Y C Gan; F Ziad; Z Thotathil; S Kirs; N A Hung; J A Royds; T L Slatter
Journal:  AJNR Am J Neuroradiol       Date:  2017-11-30       Impact factor: 3.825

10.  Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.

Authors:  Haihui Jiang; Kefu Yu; Yong Cui; Xiaohui Ren; Mingxiao Li; Guobin Zhang; Chuanwei Yang; Xuzhe Zhao; Qinghui Zhu; Song Lin
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.